PPT-Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?

Please note this program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal . Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. de cellules souches en myélome . multiple. Plan de présentation. Problématique . Méthode.  . Cadres . théoriques. Recension des . écrits. Questions . opérationnelles. Résultats. Unité d’évaluation des . Learning objectives. To understand the difference between allogeneic and autologous HSCT. To understand the types of and reasons for the different HSCT conditioning regimens. To recognise potential complications associated with HSCT. Present. . and. . Future. Mustafa CETIN. ,. . MD . December. ,. . 2016. Erciyes University BMT Center. KHUH . , Doctor . Education Program. Passweg . et al. . BMT Feb. . 2016. ASCT in . Europe (2014. Location of Centers Participating. in the CIBMTR 2014. Annual Number of Transplant Recipients in the US by Transplant Type. Transplant Recipients in the US, by Transplant and Donor Type. Cumulative Plot of Transplant Recipients in the US by Transplant Type. Current Positions:  Armand Quick – William Stapp Professor of Hematology , in the Department of Medicine in the Division of Hematology and Oncology  Se ction Head , Hematological Maligna cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Rationale. Two clinical trials. Cardiac-derived stem cells. Cedars Sinai Medical Center, Dr. Eduardo . Marban. Mesenchymal. stem cells. U. of Miami Miller School of Medicine, Dr. Joshua Hare . Challenges. December 2016. Stem Cell Therapies and MS. What do we “know. ?. ”. Advances . in stem cell medicine . provide promise . Numerous . scientific questions . about their use. Limited controlled . trials. Dr. Ali Khazaal Jumaa. F.I.B.M.S (Int. Medicine) , F.I.B.M.S (hematology). Definition :. Hematopoietic . stem cell transplantation (HSCT) involves the intravenous infusion of . autologous. or . allogeneic. Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma.